Eli Lilly's obesity pill orforglipron, marketed as Foundayo, was approved by the FDA on April 1, 2026, under the Commissioner’s Voucher program for national health priorities.1
The approval positions orforglipron in direct competition with Novo Nordisk's oral Wegovy, offering no food or drink restrictions unlike Wegovy, which must be taken 30 minutes before eating.1
Orforglipron, a small molecule oral GLP-1, showed common side effects like nausea, vomiting, and diarrhea in trials, with no liver damage risks observed.1
Lilly has stockpiled $1.5 billion worth of orforglipron and ramped up production for quick launch post-approval.27
Clinical trials demonstrated orforglipron's superior efficacy over oral semaglutide in blood sugar control and weight loss for type 2 diabetes patients.5
Analysts project orforglipron to drive Lilly's tirzepatide franchise (Mounjaro/Zepbound) to over $100 billion in peak revenue.2
Sources:
1. https://www.statnews.com/2026/04/01/eli-lilly-obesity-pill-approved-orforglipron-foundayo/
2. https://www.biospace.com/fda/6-fda-decisions-to-watch-in-q2-2026
5. https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar-control-and-weight-loss-compared-to-oral-semaglutide-in-head-to-head-type-2-diabetes-trial-published-in-the-lancet-302697632.html
7. https://www.pharmexec.com/view/eli-lilly-generates-1-billion-stockpile-orforglipron-ahead-fda-decision